Published in Gut on November 07, 2012
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet (2017) 1.41
Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol (2013) 0.99
Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.81
Determination of the human antibody response to the neutralization epitopes encompassing amino acids 313-327 and 432-443 of hepatitis C virus E1E2 glycoproteins. PLoS One (2013) 0.81
Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C. PLoS One (2015) 0.78
Organ system view of the hepatic innate immunity in HCV infection. J Med Virol (2016) 0.78
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Springerplus (2016) 0.77
Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. PLoS One (2016) 0.75
From genetic association studies to the biology of interleukin-28B in hepatitis C virus infection and beyond. Gut (2012) 0.75
Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Sci Rep (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol (2006) 4.96
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Replacement of diseased mouse liver by hepatic cell transplantation. Science (1994) 3.18
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2010) 2.68
Global epidemiology and burden of hepatitis C. Microbes Infect (2002) 2.68
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol (2004) 2.47
Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology (2007) 1.95
Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell (1990) 1.83
Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology (2005) 1.15
Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther (2006) 1.15
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res (2010) 0.99
Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. J Infect Dis (2008) 0.97
Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. J Infect Dis (2010) 0.96
Past, present, and future hepatitis C treatments. Semin Liver Dis (2004) 0.94
Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology (2011) 0.94
Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep (2008) 0.90
Viral kinetics in hepatitis C virus: special patient populations. Semin Liver Dis (2003) 0.89
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology (2003) 7.35
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol (2008) 4.55
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology (2002) 2.85
Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol (2005) 2.63
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Integration of chemosensory pathways in the Drosophila second-order olfactory centers. Curr Biol (2004) 2.49
Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem (2004) 2.32
Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med (2002) 2.23
A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol (2009) 2.20
Classifying hepatitis B virus genotypes. Intervirology (2003) 2.20
Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun (2010) 2.20
Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology (2007) 2.08
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol (2005) 2.07
What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol (2008) 2.05
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology (2003) 2.02
Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology (2012) 2.00
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol (2009) 2.00
Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol (2005) 1.97
Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology (2007) 1.95
Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol (2002) 1.82
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Identifying states of a financial market. Sci Rep (2012) 1.76
Comprehensive classification of the auditory sensory projections in the brain of the fruit fly Drosophila melanogaster. J Comp Neurol (2006) 1.75
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res (2008) 1.75
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol (2009) 1.72
A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol (2005) 1.71
Immunological effects of silica and asbestos. Cell Mol Immunol (2007) 1.69
Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology (2009) 1.66
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology (2006) 1.65
Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res (2009) 1.63
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Donor complications associated with living donor liver transplantation in Japan. Transplantation (2009) 1.60
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology (2006) 1.60
Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period. Mol Genet Metab (2008) 1.59
Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. Prev Med (2012) 1.56
Consumption of wild boar linked to cases of hepatitis E. J Hepatol (2004) 1.54
A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol (2010) 1.53
Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol (2005) 1.53
Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res (2010) 1.53
Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol (2008) 1.53
C sign for diagnosis of talocalcaneal coalition. Radiology (2003) 1.53
Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol (2004) 1.52
Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers. J Hum Genet (2010) 1.52
Cyanobacteriochrome CcaS is the green light receptor that induces the expression of phycobilisome linker protein. Proc Natl Acad Sci U S A (2008) 1.51
Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol (2002) 1.50
Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int (2014) 1.49
Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol (2005) 1.47
A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes. Gastroenterology (2013) 1.47
Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol (2005) 1.47
Visceral Abdominal Obesity Measured by Computed Tomography is Associated With Increased Risk of Colonic Diverticulosis. J Clin Gastroenterol (2015) 1.47
High-dose barium impaction therapy for the recurrence of colonic diverticular bleeding: a randomized controlled trial. Ann Surg (2015) 1.45
Transient cardiomyopathy in a patient with congenital contractural arachnodactyly (Beals syndrome). J Nippon Med Sch (2006) 1.45
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
The first report of successful nasogastric Coca-Cola lavage treatment for bitter persimmon phytobezoars in Japan. Am J Gastroenterol (2003) 1.44
Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection. J Gastroenterol (2004) 1.43
Anatomy of the ulnar artery as it relates to the transverse carpal ligament. J Hand Surg Am (2002) 1.43
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology (2006) 1.43
Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element. Mol Ther (2009) 1.43
Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res (2007) 1.40